GlassScriptPhysician profile
Jacqueline Roman
NPI 1376785881
$1,199.80
in general payments reported to CMS, 2019-2025
24 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.89 · 2020: $25.85 · 2021: $250 · 2022: $381 · 2023: $150 · 2024: $172 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $300.00 | 2022 | |
| Evofem Biosciences, INC. | $125.96 | 2021-2024 | Phexxi |
| Abbvie INC. | $123.17 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $108.74 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.96 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $51.96 | 2024-2025 | Myfembree |
| Novo Nordisk INC | $47.20 | 2025 | Ozempic, Wegovy |
| Sage Therapeutics, LLC | $46.55 | 2024 | |
| Therapeuticsmd, INC. | $41.88 | 2021-2022 | |
| Hologic Sales and Service, LLC | $38.31 | 2021-2024 | Aptima |
| Lilly USA, LLC | $38.28 | 2025 | Zepbound |
| Pfizer INC. | $33.56 | 2023-2025 | |
| Coopersurgical, INC. | $29.83 | 2021-2023 | Paragard T 380a |
| Agile Therapeutics, INC. | $27.30 | 2021 | |
| Astellas Pharma US INC | $16.73 | 2024 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $16.35 | 2025 | Femlyv |
| Organon LLC | $15.53 | 2025 | Jada System |
| Exeltis, USA INC. | $14.80 | 2020 | |
| Dysis Medical, INC. | $14.64 | 2021 | |
| Allergan, INC. | $14.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.60 | 2019 | |
| Alydia Health | $14.02 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.